Literature DB >> 3499230

Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing.

A M Honegger1, T J Dull, S Felder, E Van Obberghen, F Bellot, D Szapary, A Schmidt, A Ullrich, J Schlessinger.   

Abstract

Cultured NIH 3T3 cells devoid of endogenous EGF receptors were transfected with cDNA constructs encoding either the human EGF receptor or an EGF receptor mutant in which Lys721, a key residue in the ATP binding site, was replaced with an alanine residue. The mutant receptor was properly processed, and it displayed both high- and low-affinity surface binding sites. Unlike the wild-type receptor, the mutant receptor did not possess intrinsic protein-tyrosine kinase activity. The initial rate of EGF internalization was similar for wild-type and mutant EGF receptors. Surprisingly, the mutant receptors were not down regulated, but appeared to recycle in transfected cells. These data suggest that degradation of normal EGF receptors after endocytosis is due to the kinase activity endogenous to this receptor. A single amino acid substitution rendered a "down-regulated" receptor into a receptor that can recycle from cytoplasmic compartment back to the cell surface.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499230     DOI: 10.1016/0092-8674(87)90147-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  149 in total

1.  CHL1 is a nuclear protein with an essential ATP binding site that exhibits a size-dependent effect on chromosome segregation.

Authors:  S L Holloway
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

Review 2.  Monoclonal antibodies to epidermal growth factor receptors in studies of receptor structure and function.

Authors:  T Kawamoto; G H Sato; K Takahashi; M Nishi; S Taniguchi; J D Sato
Journal:  Cytotechnology       Date:  1990-05       Impact factor: 2.058

3.  Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation.

Authors:  Rosana D Meyer; Amrik Singh; Fredric Majnoun; Catharina Latz; Kameran Lashkari; Nader Rahimi
Journal:  Oncogene       Date:  2004-07-15       Impact factor: 9.867

Review 4.  Epidermal growth factor receptor: elements of intracellular communication.

Authors:  S M Hernández-Sotomayor; G Carpenter
Journal:  J Membr Biol       Date:  1992-06       Impact factor: 1.843

5.  Disruption of the CD4-p56lck complex is required for rapid internalization of CD4.

Authors:  B P Sleckman; J Shin; V E Igras; T L Collins; J L Strominger; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 6.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

7.  Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions.

Authors:  O Kashles; D Szapary; F Bellot; A Ullrich; J Schlessinger; A Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha.

Authors:  I Lax; A Johnson; R Howk; J Sap; F Bellot; M Winkler; A Ullrich; B Vennstrom; J Schlessinger; D Givol
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

9.  Schwannoma-derived growth factor must be transported into the nucleus to exert its mitogenic activity.

Authors:  H Kimura
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

10.  An endocytosed TGN38 chimeric protein is delivered to the TGN after trafficking through the endocytic recycling compartment in CHO cells.

Authors:  R N Ghosh; W G Mallet; T T Soe; T E McGraw; F R Maxfield
Journal:  J Cell Biol       Date:  1998-08-24       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.